lncRNA in EGFR‑driven glioblastoma
Justin D. Lathia
Nature Cell Biology, Published online: 06 May 2026; doi:10.1038/s41556-026-01947-3 EGFR amplification is common in glioblastoma and represents a therapeutic challenge, conferring resistance to targeted treatment. A new study reveals that the same locus hides the HELDR lncRNA, which epigenetically activates KAT7 to drive growth independently of EGFR. Targeting HELDR or KAT7 may improve anti-EGFR therapies in glioblastoma.